Introduction
============

Laryngeal squamous cell carcinoma (LSCC) is the most prevalent malignant tumor in the head and neck ([@b1-ol-0-0-4378],[@b2-ol-0-0-4378]). Due to the key functions of the larynx in respiration and phonation, LSCC can seriously affect the daily life of patients ([@b3-ol-0-0-4378]). At present, surgical intervention, chemotherapy and radiotherapy can be used in the treatment of primary LSCC, however, these methods have poor effects in advanced patients ([@b4-ol-0-0-4378]). Thus, there is an urgent requirement to identify genes involved in LSCC and to develop novel therapeutic schedules.

Cox proportional hazards analysis has shown that cyclin-dependent kinase inhibitor 2A point mutation is associated with disease relapse and mortality, thus, it may serve as a key biomolecular indicator in LSCC ([@b5-ol-0-0-4378],[@b6-ol-0-0-4378]). Downregulated human leukocyte antigen class I can reduce the survival time of patients with LSCC and can be used as an independent prognostic marker ([@b7-ol-0-0-4378]). The overexpression and/or co-overexpression of cyclin D1 and cyclin-dependent kinase 4 (*CDK4*) may be implicated in the biological behavior of LSCC and have a valuable prognostic significance ([@b8-ol-0-0-4378],[@b9-ol-0-0-4378]). The expression of S100 calcium binging protein A2 is associated with cytokeratin expression, cell commitment to squamous differentiation and overall survival in LSCC ([@b10-ol-0-0-4378]). Recombinant lentivirus mediated siRNA silencing of matrix metallopeptidase 2 (*MMP-2*) can suppress growth and invasion of LSCC, therefore, *MMP-2* may function in the gene therapy of LSCC ([@b11-ol-0-0-4378],[@b12-ol-0-0-4378]). Overexpressed stomatin-like protein 2 promotes cell growth, tumorigenicity and adhesion, and has a correlation with clinical stage in human LSCC ([@b13-ol-0-0-4378],[@b14-ol-0-0-4378]). In spite of studies performed to investigate LSCC, the mechanisms of LSCC remain unclear.

In the present study, to further reveal the mechanisms of LSCC, differentially-expressed genes (DEGs) were screened. Additionally, a weighted co-expression network was constructed for the DEGs and a module analysis was conducted. Additionally, the potential functions of DEGs in modules were analyzed by pathway enrichment analysis.

Materials and methods
=====================

### Microarray data

The expression profile of GSE51958, which was downloaded from Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>), was based on the platforms of GPL17869 CytoSure Human Custom Oligonucleotide 4×180 k Array v.031035 and GPL17870 CytoSure Human Custom Oligonucleotide 4×180 k Array v.025990. GSE51958 included a collection of LSCC tissue samples and matched adjacent non-cancerous tissue samples from 10 patients.

### DEG screening

Once GSE51958 was downloaded, normalized microarray data was obtained. The probes with low expression in ≥20 microarrays were excluded. According to the annotation files, probes that were corresponding to any genes were eliminated. Subsequently, the limma (linear models for microarray data) package ([@b15-ol-0-0-4378]) (<http://www.bioconductor.org>) was used to screen the DEGs between the LSCC samples and matched adjacent non-cancerous samples. The adjusted P-value of \<0.05 and \|logfold change (FC)\|≥1 were used as the cut-off criteria.

### Weighted co-expression network construction

The WGCNA package ([@b16-ol-0-0-4378]) in R was used to construct weighted co-expression networks for the DEGs. Briefly, Pearson\'s correlation coefficients between the DEGs were calculated using their expression matrices. The correlation coefficient of ≥0.8 was defined as the weighting coefficient.

A hierarchical clustering tree was constructed for the DEGs using the hybrid dynamic shear tree method ([@b17-ol-0-0-4378]), and branches of the clustering tree represented the gene modules. Each module had to be involved with at least 10 genes. Afterwards, the feature vector of each module (module eigengenes) was calculated and cluster analysis was performed for the modules. The closed modules (difference of feature vectors \<0.15) were merged into new modules. Furthermore, correlation analysis between modules and LSCC was performed. Gene significance (GS) and module significance (MS; the mean value of all GS values) were calculated. The module with the highest MS had a closer correlation with LSCC.

### Pathway enrichment analysis

The Kyoto Encyclopedia of Genes and Genomes (KEGG) is a reference knowledge base involving systems information, genomic information and chemical information ([@b18-ol-0-0-4378]). Using the clusterProfiler package ([@b19-ol-0-0-4378]) (<http://bioconductor.org/packages/release/bioc/html/clusterProfiler.html>), KEGG pathway enrichment analyses were conducted separately for the DEGs in the modules. A P-value of \<0.1 was used as the cut-off criterion.

Results
=======

### DEG analysis

When compared with the adjacent non-cancerous samples, a total of 959 DEGs were screened from the LSCC samples, including 553 upregulated and 406 downregulated genes. Evidently, there were more upregulated genes than downregulated genes.

### Weighted co-expression network construction

The weighted co-expression network was constructed and the weighting coefficient was set as 17 ([Fig. 1](#f1-ol-0-0-4378){ref-type="fig"}). Modules were identified from the weighted co-expression network. After these closed modules were merged, a total of 5 modules (appointed the black, brown, gray, pink and yellow modules to distinguish the 5 modules) were screened for the DEGs ([Fig. 2](#f2-ol-0-0-4378){ref-type="fig"}). According to the result of the correlation analysis, their MS values were approximately the same ([Table I](#tI-ol-0-0-4378){ref-type="table"}). The pink and black modules contained mainly upregulated genes. By contrast, the brown and yellow modules mainly contained downregulated genes. Furthermore, the numbers of upregulated genes and downregulated genes were the same in the gray module.

### Pathway enrichment analysis

Using the clusterProfiler package, pathway enrichment analyses were conducted separately for the DEGs in each module. However, only the DEGs in the brown, pink and yellow modules were involved in pathways. For the DEGs in the brown and yellow modules, the enriched pathways were the cytokine-cytokine receptor interaction and metabolic pathways, respectively. There were 13 enriched pathways for the DEGs in the pink module, including cell cycle (P=2.05×10^−8^), pathways in cancer (P=1.86×10^−2^) and focal adhesion (P=5.93×10^−2^) ([Table II](#tII-ol-0-0-4378){ref-type="table"}).

The connectivity distribution of the DEGs in the pink module is shown in [Fig. 3](#f3-ol-0-0-4378){ref-type="fig"}. In the pink module, the DEGs with connectivity degrees \>20 were upregulated in LSCC samples. In particular, TPX2, microtubule-associated homolog (*TPX2*; degree, 25), minichromosome maintenance complex component 2 (*MCM2*; degree, 25), ubiquitin-like with PHD and ring finger domains 1 (*UHRF1*; degree, 22), cyclin-dependent kinase 2 (*CDK2*; degree, 20) and protein regulator of cytokinesis 1 (*PRC1*; degree, 20) exhibited high connectivity degrees in the pink module.

Discussion
==========

In the present study, a total of 959 DEGs, including 553 upregulated genes and 406 downregulated genes, were screened from LSCC samples compared with adjacent non-cancerous samples. A total of 5 modules (the black, brown, gray, pink and yellow modules) were screened for the DEGs in the weighted co-expression network. The DEGs in the pink module were involved in the most pathways. *TPX2* (degree, 25), *MCM2* (degree, 25), *UHRF1* (degree, 22), *CDK2* (degree, 20) and *PRC1* (degree, 20) may be of great importance in LSCC, as they had high connectivity degrees in the pink module.

As a serine-threonine kinase gene, Aurora-A may correlate with *TPX2* during spindle assembly, and *TPX2* functions in targeting Aurora-A to the spindle apparatus ([@b20-ol-0-0-4378]). Aurora-A and *TPX2* are often co-overexpressed, therefore, certain functions of Aurora-A in cell transformation and tumorigenesis can be a result of the oncogenic activation of the Aurora-A/TPX2 complex ([@b21-ol-0-0-4378]). Upregulated Aurora-A may play important roles in the tumor progression and prognosis of head and neck squamous cell carcinoma ([@b22-ol-0-0-4378]). By enhancing the invasion ability and chromosomal instability, overexpressed Aurora-A may promote the carcinogenesis and progression of LSCC ([@b4-ol-0-0-4378],[@b23-ol-0-0-4378]). Thus, the expression level of *TPX2* may be associated with LSCC.

As a biomarker for showing the proliferation of laryngeal carcinoma cells, *MCM2* can play a role in the occurrence, progression and prognosis of laryngeal carcinoma ([@b24-ol-0-0-4378]). It has been reported that overexpressed *UHRF1* may function in the progression of LSCC and may be used as a promising marker for the prognosis of LSCC ([@b25-ol-0-0-4378]). By transforming cell cycle progression, promoting apoptosis and weakening the DNA damage repair capacity, the inhibition of *UHRF1* can be implicated in the radioresistance of esophageal SCC ([@b26-ol-0-0-4378]). The results indicate that *MCM2* and *UHRF1* may have a close correlation with LSCC.

Cyclin D1, cyclin E and their catalytic subunits, *CDK4* and *CDK2*, often are overexpressed in a number of human esophageal SCC cases ([@b27-ol-0-0-4378]). The overexpression of combined *CDK2* and proliferating cell nuclear antigen indicates a poor overall survival time, and *CDK2* expression may be associated with the biological behavior of LSCC ([@b28-ol-0-0-4378]). Overexpressed cyclin E has a correlation with poor clinicopathological parameters and can serve as an biomarker for cell proliferation and prognosis in patients with LSCC ([@b29-ol-0-0-4378]). These results may indicate that the expression level of *CDK2* is associated with LSCC. As a protein implicated in cytokinesis, PRC1 is a good *in vivo* substrate for several CDKs ([@b30-ol-0-0-4378]), indicating that *PRC1* may also play a role in LSCC through *CDK2*.

In conclusion, the present study performed an integrated bioinformatics analysis of genes that may be associated with LSCC. A total of 959 DEGs were screened from LSCC samples compared with adjacent non-cancerous samples. Furthermore, *TPX2*, *MCM2*, *UHRF1*, *CDK2* and *PRC1* may play a role in LSCC. However, further studies are required to reveal their specific functions in LSCC.
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###### 

Statistics for the five modules (black, brown, gray, pink and yellow modules).

           Size    ME-LSCC correlation                          
  -------- ------- --------------------- -------- ------------- ------
  Black      40        1                   0.81   1.82×10^−5^   0.68
  Pink     414     104                     0.86   1.21×10^−6^   0.69
  Brown      55    203                   −0.85    2.36×10^−6^   0.69
  Yellow     36      90                  −0.84    4.26×10^−6^   0.69
  Gray         8       8                 −0.92    9.84×10^−9^   0.65

ME, module eigengenes; MS, module significance; LSCC, laryngeal squamous cell carcinoma; ME-LSCC correlation, pearson correlation coefficients between ME and LSCC.

###### 

Pathways enriched for differentially-expressed genes in the pink, brown and yellow module.

  Module   Category   Term    Description                              Gene number   Gene                                                                                                                            P-value
  -------- ---------- ------- ---------------------------------------- ------------- ------------------------------------------------------------------------------------------------------------------------------- --------------
  Pink     KEGG       03030   DNA replication                          12            FEN1, MCM2, MCM3, MCM4, RFC5, RFC4, DNA2, POLA2, RNASEH2A, PRIM2, POLE2, PRIM1                                                  6.02×10^−10^
           KEGG       04110   Cell cycle                               19            CDK4, CDK2, MCM2, PRKDC, MCM3, MCM4, CDC25B, ORC1, PKMYT1, CDC25A, SKP2, CDC20, TTK, MAD2L1, CDC45, CHEK1, CCNB1, CCNE1, CDK6   2.05×10^−8^
           KEGG       05222   Small cell lung cancer                   10            CDK4, CDK2, LAMA3, COL4A1, LAMB3, LAMC2, COL4A2, SKP2,                                                                          3.81×10^−4^
           KEGG       00240   Pyrimidine metabolism                    10            CCNE1, CDK6, NME1, UCK2, TK1, POLA2, PRIM2, POLR3D, POLE2, TYMP, TYMS, PRIM1                                                    1.28×10^−3^
           KEGG       04115   P53 signaling pathway                      8           SESN3, CDK4, CDK2, IGFBP3, CHEK1, CCNB1, CCNE1, CDK6                                                                            1.61×10^−3^
           KEGG       04512   ECM-receptor interaction                   8           SPP1, LAMA3, COL4A1, TNC, LAMB3, LAMC2, COL4A2, ITGB4                                                                           5.98×10^−3^
           KEGG       05200   Pathways in cancer                       18            CDK4, CDK2, LAMA3, PDGFB, COL4A1, SLC2A1, LAMB3, LAMC2, COL4A2, SKP2, BIRC5, DVL3, EGFR, AR, WNT3, WNT7B, CCNE1, CDK6           1.86×10^−2^
           KEGG       04510   Focal adhesion                           11            SPP1, LAMA3, PDGFB, COL4A1, TNC, LAMB3, LAMC2, COL4A2, CAV2, EGFR, ITGB4                                                        5.93×10^−3^
  Brown    KEGG       04060   Cytokine-cytokine receptor interaction   7             CXCL12, LEPR, CCL15, CCL28, CCL14, KIT, TNFRSF12A                                                                               5.05×10^−2^
  Yellow   KEGG       01100   Metabolic pathways                       14            ATP6V0A4, FUT6, ST6GALNAC1, GCNT3, ACSM3, EPHX2, AKR1B1, GGT6, GALE, FUT2, MGLL, TM7SF2, CYP3A5, B3GNT3                         1.34×10^−2^

ECM, extracellular matrix; KEGG, Kyoto Encyclopedia of Genes and Genomes.
